AstraZeneca Plc to sell commercial rights of Atacand and Atacand Plus in around 70 countries

Be the First to Comment Read

AstraZeneca Plc to sell commercial rights of Atacand and Atacand Plus in around 70 countries

AstraZeneca Plc (LON: AZN) has agreed to sell the commercial rights of two of its medicine Atacand and Atacand Plus in around 70 countries across the globe to Cheplapharm Arzneimittel GmbH.

  • The company will receive a total of $400million in non-contingent consideration from Cheplapharm, of which $250million will be payable on completion and the remainder in the first half of 2021.
  • The company will continue to manufacture and supply Atacand (candesartan cilexetil) used for or the treatment of heart failure and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) used for the treatment of hypertension.
  • It will also continue to commercialise medicine during a three-year transition period.
  • On 30 October 2020, the stocks of the company declined by 0.60% from its previous closing, hovering at around GBX 7,829.00 at 10:35 AM GMT+1.

Disclaimer

Speak your Mind